Study examines safety, immune response of candidate Ebola vaccines

A phase 1 trial has been conducted to evaluate the tolerability and immunogenicity of two candidate Ebola vaccines, an adenovirus type 26 vector vaccine (Ad26.ZEBOV), and a modified Ankara vector vaccine (MVA-BN-Filo).